Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment

Paper Details

Authors:

Florencia P. Madorsky Rowdo

Gu Xiao

Galina Khramtsova

John Nguyen

Olufunmilayo I. Olopade

Rachel Martini

Brian Stonaker

Richard Boateng

Joseph K. Oppong

Ernest Adjei

Baffour Awuah

Ishmael Kyei

Frances S. Aitpillah

Michael O. Adinku

Kwasi Ankomah

Ernest Osei‐Bonsu

Kofi K. Gyan

Nasser K. Altorki

Esther Cheng

Paula S. Ginter

Syed A. Hoda

Lisa A. Newman

Olivier Elemento

Melissa B. Davis

M. Laura Martín

Jill Bargonetti

Publication Date: 2023-06-22

PARP inhibition in cancer therapyMedicineOncologyHealth Sciences

Read Paper

External Resources

View on DOI

Paper information is provided by public research databases. Summaries are generated to aid understanding and may not reflect the complete scope of the work. For the authoritative version, please refer to the original publication.